Kaken Pharmaceutical's forecast ordinary profit for the fiscal year ending March 2027 is expected to be ¥7,466 million, up 28.7% week on week, but remains below the company's forecast of ¥8,600 million. The rating consensus remains at 3.5.
The consensus forecast for Kaken Pharmaceutical's ordinary profit for the fiscal year ending March 2027 has been raised substantially from the previous week and is expected to reach ¥7,466 million.
At ¥8,600 million, the company's forecast remains below the market's assessment of its earnings capacity, and the consensus is said to continue to reflect a relatively bearish view.
Ono Pharmaceutical, SanBio, Morishita Jintan and Eisai are among the stocks frequently cited alongside the company.
The article is based on information provided by IFIS Japan, which can be verified through the related link.